Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Apr 14;18(4):837. doi: 10.3390/ijms18040837

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Overall survival of AEL patients stratified by type of first line treatment. (A) Total cohorts: median OS for patients treated with first-line HMA was similar to that of those treated with first-line ICT (13.7 months vs. 10.5 months; p = 0.564); (B) stratified by MRC intermediate cytogenetic risk: AEL-patients with intermediate-risk cytogenetics treated with first-line HMA did not have a significantly different median survival as compared to AEL-patients treated with first-line ICT (16.9 months vs. 29.3 months; p = 0.277); and (C) stratified by MRC high cytogenetic risk: AEL-patients with high-risk cytogenetics treated with first-line HMA had a significantly longer median survival as compared to AEL-patients treated with first-line ICT (13.3 months vs. 7.5 months; p = 0.0391).

Overall survival of AEL patients stratified by type of first line treatment. (A) Total cohorts: median OS for patients treated with first-line HMA was similar to that of those treated with first-line ICT (13.7 months vs. 10.5 months; p = 0.564); (B) stratified by MRC intermediate cytogenetic risk: AEL-patients with intermediate-risk cytogenetics treated with first-line HMA did not have a significantly different median survival as compared to AEL-patients treated with first-line ICT (16.9 months vs. 29.3 months; p = 0.277); and (C) stratified by MRC high cytogenetic risk: AEL-patients with high-risk cytogenetics treated with first-line HMA had a significantly longer median survival as compared to AEL-patients treated with first-line ICT (13.3 months vs. 7.5 months; p = 0.0391).